Trial results announced on Tuesday [June 16] by researchers in Britain showed dexamethasone, used since the 1960s to reduce inflammation in diseases such as arthritis, cut death rates by around a third among the most severely ill COVID-19 patients admitted to hospital.
[Editor’s note: The World Health Organization is planning to update its guidance on treating severely ill coronavirus COVID-19 patients after a British clinical trial showed that a common steroid can help.]
The WHO’s clinical guidance for treating patients infected with the new coronavirus is aimed at doctors and other medical professionals and seeks to use the latest data to inform clinicians on how best to tackle all phases of the disease, from screening to discharge.
Although the dexamethasone study’s results are preliminary, the researchers behind the project said it suggests the drug should immediately become standard care in severely stricken patients.
For patients on ventilators, the treatment was shown to reduce mortality by about one third, and for patients requiring only oxygen, mortality was cut by about one fifth, according to preliminary findings shared with WHO.
The benefit was only seen in patients seriously ill with COVID-19 and was not observed in patients with milder disease.
“This is the first treatment to be shown to reduce mortality in patients with COVID-19 requiring oxygen or ventilator support,” WHO Director-General Tedros Adhanom Ghebreyesus said in a statement late on Tuesday.